Satellos Bioscience Inc.
MSCL.V
Toronto Stock Exchange Ventures0.56
CAD
+0.01
- -
Satellos Bioscience Inc.
MSCL.V
(Toronto Stock Exchange Ventures)
Recent
price
0.56
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Satellos Bioscience Inc. is a biotechnology company focused on developing life-improving medicines for degenerative muscle diseases. The company applies its proprietary discovery platform, MyoReGenX™, to identify muscle diseases characterized by impaired muscle stem cell polarity and defective muscle regeneration, aiming to develop novel therapeutics that restore the body’s innate muscle repair process. Its main product pipeline centers on an orally administered small molecule drug candidate, SAT-3247, designed as a potential disease-modifying treatment for Duchenne muscular dystrophy (DMD) by correcting muscle stem cell polarity dysregulation. Satellos also holds rights to clinical-stage legacy assets acquired through its 2021 reverse merger acquisition of iCo Therapeutics Inc. The company operates primarily in Canada and is headquartered in Toronto, Ontario, with a founding year in 2018. Recent major developments include the submission of an Investigational New Drug (IND) application to the U.S. FDA and corresponding global regulatory filings to initiate a Phase 2 clinical trial of SAT-3247 in children with DMD, with patient enrollment expected by the end of 2025. The Phase 1b studies reported encouraging results showing safety, tolerability, and functional gains such as improved grip strength and lung function in adults with DMD. Satellos also initiated an 11-month extension study in Australia and plans a global Phase 2 randomized trial pending regulatory approvals. Furthermore, the company expanded its strategic positioning through a partnership with Jesse's Journey, a Canadian leader in Duchenne research, supporting development and infrastructure. Satellos' wholly owned subsidiary, Amphotericin B Technologies Inc., entered a joint venture with NW PharmaTech Ltd. to develop an oral cannabidiol formulation for mental health indications. Financially, Satellos raised CAD 1.04 million through warrant exercises in Q3 2025, with ongoing fundraising and clinical development progress reinforcing its pipeline advancement. Overall, Satellos Bioscience Inc. specializes in the discovery and clinical development of oral therapeutics targeting regenerative deficits in muscle diseases, with a current focus on Duchenne muscular dystrophy and strategic growth through acquisitions, partnerships, and clinical milestones aimed at addressing degenerative muscle disorders globally.